Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
RLAY reporting person Sekar Kathiresan filed to sell common stock. The planned transaction covers 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on or about July 31, 2026 on NASDAQ, with an indicated value of $563,553.00.
The filing also lists prior sales within three months: 30,000 shares of common stock on July 21, 2026 for $594,414.00, and 66,055 shares on July 20, 2026 for $1,293,555.07. The planned sale is linked to a stock option exercise settled in cash.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported the sale of 1,459 shares of common stock on July 28, 2026 at $18.61 per share. The shares were sold solely to cover income tax withholding from the vesting of 3,269 RSUs, with no discretion by the officer and in line with company policies. After the sale, he beneficially owns 158,285 shares, including 6,538 shares underlying RSUs.
Relay Therapeutics, Inc. officer Peter Rahmer, Chief Corporate Development Officer, had 748 shares of common stock sold on July 28, 2026 at $18.61 per share to cover income tax withholding from the vesting of 3,051 RSUs. He had 228,165 shares remaining afterward, including 6,102 shares underlying RSUs, and no discretion over the tax-related sale, which followed the company’s RSU vesting policies.
Relay Therapeutics, Inc. executive Donald A. Bergstrom, President of R&D, reported the sale of 2,237 shares of common stock on July 28, 2026 at $18.61 per share. The sale covered income tax withholding on the vesting of 5,012 RSUs on July 27, 2026. After the transaction, he directly held 407,660 shares, including 10,025 shares underlying RSUs.
Relay Therapeutics insider Sekar Kathiresan filed a notice to sell company stock. The filing covers a proposed sale of 30,000 shares of common stock of Relay Therapeutics through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $594,414.00, expected on July 21, 2026. The shares are tied to a stock option exercise by the issuer for cash. The filing also reports that, during the past three months, 66,055 shares of common stock were sold on July 20, 2026 for total proceeds of $1,293,555.07.
Relay Therapeutics’ President of R&D, Donald A. Bergstrom, reported an open-market sale of 8,660 shares of common stock at a weighted average price of $18.71 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, he directly holds 409,897 shares, including 15,037 shares underlying restricted stock units.
Relay Therapeutics, Inc. President and CEO Sanjiv Patel reported routine equity activity involving company common stock. On June 30, 2026, he acquired 3,056 shares through the company’s Employee Stock Purchase Plan at $6.95 per share, a plan-based purchase described as exempt under Rule 16b-3.
On July 7, 2026, he sold 48,199 shares of common stock in an open-market transaction at a weighted average price of $19.58 per share, executed in multiple trades between $18.52 and $20.20 pursuant to a pre-established Rule 10b5-1 trading plan adopted on October 30, 2025. Following these transactions, Patel directly holds 615,898 shares of Relay Therapeutics common stock.
Separate from his direct holdings, irrevocable trusts for the benefit of his family members hold 687,355 shares and 199,548 shares of common stock, respectively, with an independent trustee. Patel disclaims beneficial ownership of the shares held in these trusts.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock in open-market transactions on July 6, 2026 at a weighted average price of $18.69 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025, meaning the sales were scheduled in advance.
The sale was completed in multiple trades at prices ranging from $18.39 to $19.38 per share. After these transactions, Catinazzo directly owns 159,744 shares of Relay Therapeutics common stock, which includes 9,807 shares underlying restricted stock units.